Subject(s)
Antibodies/diagnosis , Complement C3/immunology , Fluorescent Antibody Technique/methods , Fluorescent Antibody Technique, Direct , Fluorescent Antibody Technique, Indirect/methods , Humans , Immune System Diseases/diagnosis , Immunoglobulin G/blood , Lichen Planus/diagnosis , Pemphigus/blood , Skin Diseases/diagnosisABSTRACT
The present study was designed to evaluate the frequency of anemia of chronic diseases [ACD] in patients with systemic lupus erythematosus [SLE] and to estimate serum levels of interleukin-6 [IL-6] and erythropotien [EPO] and to determine the serum positivity for antibodies to human EPO [anti-EPO antibodies] in patients with ACD so as to evaluate their probable role in pathogenesis of ACD. The study included 200 patients with SLE; all underwent clinical evaluation of disease activity using the British Isles Lupus Assessment Group [BILAG] score and laboratory assessment of immunologic parameters. Hemoglobin concentration [Hb cone.] was determined and anemia was defined by haemoglobin concentration [Hb cone.] of
Subject(s)
Humans , Male , Female , Anemia , Chronic Disease , Interleukin-6/blood , Erythropoietin/blood , Antibodies , Complement C3/immunology , Complement C4/immunologyABSTRACT
Inflammatory response in the atherosclerotic lesions of coronary artery disease, mediated by cellular immune mechanisms is well appreciated. The significance of the immuno-inflammatory processes for the development of acute ischaemic sequelae of these lesions remains unsettled. Fifty patients of acute coronary syndromes were studied for complement components and immunoglobin levels by single radial immunodiffusion method. Twenty-eight patients of acute myocardial infarction showed significantly lower levels of complement components C3 and C4 at admission (C3--69.19 +/- 12.91 mg% compared to 82.40 +/- 9.26 mg% in controls, p < 0.01; C4--14.56 +/- 2.46 mg% compared to 18.53 +/- 2.69 mg% in controls, p < 0.01). Twenty-two patients of unstable angina did not show any significant change (C3--83.14 +/- 8.01 mg% and C4--19.07 +/- 4.47 mg%). Sixteen patients of acute myocardial infarction who were thrombolysed with streptokinase showed a steep rise in the levels of complement components immediately after thrombolysis (C3--69.19 +/- 12.91 mg% before and 100.56 +/- 17.09 mg% after thrombolysis, p < 0.001; C4--14.56 +/- 2.46 mg% before and 21.48 +/- 4.78 mg% after thrombolysis, p < 0.001). Plasma C3 and C4 levels in acute myocardial infarction showed no relationship with peak CPK levels. Plasma immunoglobulins remained unchanged in patients of acute coronary syndromes.
Subject(s)
Adult , Aged , Angina, Unstable/drug therapy , Biomarkers/blood , Complement C3/immunology , Complement C4/immunology , Creatine Kinase/blood , Female , Fibrinolytic Agents/therapeutic use , Humans , Immunoglobulins/blood , Male , Middle Aged , Myocardial Infarction/drug therapy , Prognosis , Streptokinase/therapeutic use , Thrombolytic TherapyABSTRACT
We have evaluated the status of cardiac immune complexes and heart reactive antibodies in endomyocardial biopsies (EMB) and patients' sera from cases of dilated cardiomyopathy (DCM) using immunofluorescence. This was done with an aim to test whether this parameter can be of diagnostic and/or prognostic value in cases of DCM in its inflammatory and non inflammatory stages. Deposition of IgG was consistently observed in all cases of DCM regardless of the presence or absence of inflammation. Complement was detected in only a few while IgG and C3 together was seen to be deposited in only 4 cases. IgA and IgM were noted in an occasional case only. Heart reactive antibodies were seen in 13 of the 23 cases of DCM. Light microscopically, in 7 of the 23 biopsies mild focal lymphocytic myocarditis was detected. Presence of IgG in EMB and a low left ventricular ejection fraction (LVEF 35%) in almost all the cases, highlight the prognostic significance of IgG (in EMB) as an independent parameter. Based on this small study, it is difficult to attach significance to these observations as regards predicting the outcome of these patients. Nevertheless, the present study initiates evaluation of one of the parameters which is accessible and can be easily carried out in most routine laboratories for diagnosis, prognosis, and eventually monitoring of therapy in patients of DCM. Importance of immunofluorescence technique can be further strengthened by evaluating a larger number of cases with varying duration of symptoms and a follow up study of cases of DCM.
Subject(s)
Adolescent , Adult , Antibodies/analysis , Antigen-Antibody Complex/analysis , Biopsy , Cardiomyopathy, Dilated/immunology , Child , Complement C3/immunology , Female , Fluorescent Antibody Technique , Humans , Immunoglobulins/immunology , Male , Middle Aged , Myocardium/immunology , PrognosisABSTRACT
The major complement component, C3, is the substrate for C3 convertases which emerge by activation of the classical and alternative complement pathways; fragments C3b and C3a are the resulting split products. The C3b becomes a constituent of the amplification C3-convertase in the alternative pathway, and of the C5 convertases responsible for the organization of the potentially cytolytic complex C5b-C9, being also able to interact with numerous serum proteins, cell surface molecules and foreign protein. The C3a functions as mediator of the early events of teh inflamatory process. Recent observations on the molecular features involved in the multiple interaction of C3 characterize this proteins as a most versatile and multifunctional molecule which is also an important participant of both the immune and monimmune surveillance mechanism